Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
about
Mechanism of action of lenalidomide in hematological malignanciesCurrent and emerging treatment options for patients with relapsed myelomaTreatment of multiple myeloma bone disease: experimental and clinical data.Management of the adverse effects of lenalidomide in multiple myeloma.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Lenalidomide in multiple myeloma: current experimental and clinical data.The use of novel agents in the treatment of relapsed and refractory multiple myelomaLong-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature.Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Current multiple myeloma treatment strategies with novel agents: a European perspectiveLenalidomide in multiple myeloma: current role and future directions.Cost-effectiveness of lenalidomide in multiple myeloma.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Managing multiple myeloma in the elderly: are we making progress?Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Understanding the molecular biology of myeloma and its therapeutic implications.Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.Current Review on High-Risk Multiple Myeloma.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Trial Watch: Lenalidomide-based immunochemotherapy.Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.Lenalidomide in multiple myeloma.Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
P2860
Q21198872-20B4A48D-DE60-40F6-84CC-FE17177834E9Q26830878-A78CDA5F-0B83-416C-B564-F2B24D95BDEBQ30868833-58168FC5-45D0-4C95-93BD-66BFCB8B47DCQ33394632-A95A263F-C47D-418B-A83B-19D598573858Q33401457-4ACCE330-4598-40D4-B2D8-6A53D54E639BQ33403183-DCA879CD-A060-4A1D-B2E8-50D2D0D68D36Q33437691-CB860989-C08A-41FD-9BC7-1F8F36225CE2Q34074803-A01A3DBB-D491-4826-8940-CB0C386F8D35Q35097319-25EA3FE1-8079-4909-9269-FEFA7C0F5D8FQ35592482-7B2DC37F-D2A7-48F1-9A9E-26D89723C678Q36612669-12BF4CBD-E586-45FA-ACE6-1A743BB827BDQ37507513-D9650D26-41F5-4BCD-BD2E-86702D668356Q37677935-913BB2F4-A724-4FC9-B358-5963356C95A9Q37704401-796DFF45-A93C-4692-A4AF-825714A3D364Q37764870-94DBB4C2-5A68-4667-AC83-7510768F786BQ37800884-35BE5782-9319-434D-A435-760487CA5675Q37829230-F7C5ABC8-1F36-43E6-B114-77964AFC2F8EQ37831402-AF04BBCF-90F9-41E5-A16C-897773F6E73EQ37835695-05FB2DE5-5A75-49A5-BCA3-0EA44EDD5AF9Q37862262-E986DBFB-B7A9-44A4-A84B-E2554A95C5ABQ37888716-D7168E4E-F561-4FD7-BF02-6D25F1DD2530Q37949201-766B1B7B-C5DF-461C-807A-4923BE67851FQ38031989-9FD264C7-AF30-4D00-8F40-782D349A36E6Q38065305-DC0C4106-9A7C-409F-B2B4-F4D94D41161DQ38169586-727C5DE1-76C4-466E-9EC4-1BE406214A24Q38170453-349EE362-68AF-435D-B922-579B451EC49AQ38261677-93C57030-D02A-46B2-9471-732F413B0A55Q38545607-18B09808-9D40-4EDC-A7DA-5AD4360EE2D3Q38608267-A93B5AE1-0D48-4578-A337-751F781F6861Q38895167-12FACE6C-6CD4-474F-AE17-04E77DD16611Q39065368-2D72FFD8-9C3E-452C-A8B2-3BD3D1E5308CQ39177792-7B81B6FE-577F-4067-8BA2-6635F003ECF5Q39524467-3DDBDD95-CB61-4219-B67B-361DE24758A5Q42737828-4766A041-07D0-42B1-A5EF-6D10D25AFACBQ42925566-EE18B09B-38C0-4871-83D6-83ACC8F1FF70Q43247044-1A59610E-5C74-4E80-BB5A-00E96DDB3D30Q44469916-D328C57D-3F95-440C-B697-A62C660F2CF4Q44512399-2A430B41-982B-4452-9792-251B42EBC7BFQ44781560-5DBA9D80-3D21-45D8-A1E7-601D8D3AF802Q48204298-948E557A-4BB3-4BC1-AF04-A3B24A376898
P2860
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@ast
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@en
type
label
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@ast
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@en
prefLabel
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@ast
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@en
P2093
P1433
P1476
Lenalidomide, adriamycin, and ...... udiengruppe Multiples Myelom).
@en
P2093
Axel Glasmacher
Christian Gerecke
Christina Vollmuth
Karina Falk
Max S Topp
Orhan Sezer
Peter Liebisch
Ralf C Bargou
Stefan Knop
Uwe Maeder
P304
P356
10.1182/BLOOD-2008-10-184135
P407
P577
2009-01-30T00:00:00Z